MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2

Launched by GUSTAVE ROUSSY, CANCER CAMPUS, GRAND PARIS · Jan 19, 2023

Keywords

ClinConnect Summary

The clinical trial titled MAPPYACTS 2 is looking at how to improve cancer treatment for children and young adults with solid tumors or leukemia that have not responded to standard therapies. This study builds on previous research that analyzes the unique genetic features of each patient’s tumor to find tailored treatment options that might work better for them. By collecting detailed information about the tumors and the patients' health, the trial aims to connect patients with potential new treatments and help doctors make more informed decisions about their care.

To take part in this trial, participants need to be 25 years old or younger at the time of their initial cancer diagnosis and must have a tumor or leukemia that has come back or hasn’t responded to previous treatments. They also need to provide consent for their tumor to be analyzed and for researchers to collect information about their health and treatment outcomes. Throughout the trial, participants can expect discussions with a team of experts who will review their test results and recommend the best treatment options. This trial not only offers hope for better care but also plays a crucial role in advancing cancer research for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient referred for sequencing of the tumor within the FMG2025 or equivalent program and written informed consent for FMG2025 "Cancers et leucémies pédiatriques en échec de traitement" or equivalent, according to local regulations
• • Written informed consent of MAPPYACTS 2 to collect molecular and comprehensive clinical data on cancer diagnosis, therapies, therapy outcomes, to provide clinical therapeutic recommendations, to collect follow-up data on treatment and patients' outcome; optional written consents to perform to ancillary research studies, according to local regulations. The written consent will include access to reimbursement data from the French national health insurance through linkage with the Système National des Données de Santé (SNDS) or equivalent.
• • Patient with histologically/cytologically confirmed solid tumor or leukemia which is relapsed or refractory to standard treatment and who is potentially eligible for an experimental treatment or an early phase clinical trial
• • Planned tumor biopsy, surgical resection, bone marrow or blood sample or recently (preferably within the last 3 months) archived frozen tumor material available of the current recurrent or refractory disease
• • Patients aged ≤ 25 years at the time of initial diagnosis
• • Performance status and life expectancy \> 3 months expected to allow enrolment into an clinical trial
• • Patients affiliated with a Social Security Regimen or beneficiary of the same, as per local regulatory requirements
• Exclusion Criteria:
• • Any concurrent illness or laboratory abnormality that, in the opinion of the investigator, is likely to interfere with the interpretation of study results
• • Pregnant women